300639 Stock Overview
Engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.73 |
| 52 Week High | CN¥11.19 |
| 52 Week Low | CN¥4.68 |
| Beta | 0.43 |
| 11 Month Change | -21.17% |
| 3 Month Change | -36.68% |
| 1 Year Change | -49.73% |
| 33 Year Change | -66.76% |
| 5 Year Change | -7.51% |
| Change since IPO | 20.71% |
Recent News & Updates
Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065
May 22
There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings
May 03Shareholder Returns
| 300639 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -6.0% | -4.5% | -1.6% |
| 1Y | -49.7% | -20.4% | -15.7% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -20.4% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned -15.7% over the past year.
Price Volatility
| 300639 volatility | |
|---|---|
| 300639 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300639's share price has been volatile over the past 3 months.
Volatility Over Time: 300639's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,669 | Jianyu Wang | www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
| 300639 fundamental statistics | |
|---|---|
| Market cap | CN¥3.04b |
| Earnings (TTM) | CN¥60.76m |
| Revenue (TTM) | CN¥985.44m |
50.0x
P/E Ratio3.1x
P/S RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300639 income statement (TTM) | |
|---|---|
| Revenue | CN¥985.44m |
| Cost of Revenue | CN¥417.24m |
| Gross Profit | CN¥568.21m |
| Other Expenses | CN¥507.44m |
| Earnings | CN¥60.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.095 |
| Gross Margin | 57.66% |
| Net Profit Margin | 6.17% |
| Debt/Equity Ratio | 0.6% |
How did 300639 perform over the long term?
See historical performance and comparison